Cyclotherapy: Opening a therapeutic window in cancer treatment

Oncotarget

Volumn 3, Issue 6, 2012, Pages 596-600

  van Leeuwen, Ingeborg M M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Actinomycin D; Chemotherapy; Cyclotherapy; Leptomycin B; Nutlin 3; P53; Tenovin 6

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IMATINIB; NAVELBINE; PROTEIN KINASE C DELTA; SOMATOMEDIN C; VINCRISTINE SULFATE;

ANEMIA; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CONCENTRATION RESPONSE; CYCLOTHERAPY; CYTOSTASIS; CYTOTOXICITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; RISK ASSESSMENT; RISK FACTOR; S PHASE CELL CYCLE CHECKPOINT;

EID: 84868615579     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.524     Document Type: Article

References (34)

1. Chabner BA and Roberts TG, Jr. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer. 2005; 5(1):65-72.
2. DeVita VT, Jr. and Chu E. A history of cancer chemotherapy. Cancer Res. 2008; 68(21):8643-8653.
3. Blagosklonny MV. Analysis of FDA approved anticancer drugs reveals the future of cancer therapy. Cell Cycle. 2004; 3(8):1035-1042.
4. Sikora K, Advani S, Koroltchouk V, Magrath I, Levy L, Pinedo H, Schwartsmann G, Tattersall M and Yan S. Essential drugs for cancer therapy: a World Health Organization consultation. Ann Oncol. 1999; 10(4):385-390.
5. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J and Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2(5):561-566.
6. Blagosklonny MV and Darzynkiewicz Z. Cyclotherapy: protection of normal cells and unshielding of cancer cells. Cell Cycle. 2002; 1(6):375-382.
7. Blagosklonny MV and Pardee AB. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res. 2001; 61(11):4301-4305.
8. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC and Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res. 2005; 65(5):1918-1924.
9. Kranz D and Dobbelstein M. Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy. Cancer Res. 2006; 66(21):10274-10280.
10. van Leeuwen IM, Rao B, Sachweh MC and Lain S. An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells. Cell Cycle. 2012; 11(9):1851-1861.
11. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, McCarthy A, Appleyard V, Murray KE, Baker L, Thompson A, Mathers J, Holland SJ, Stark MJ, Pass G, Woods J, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008; 13(5):454-463.
12. Lain S, Midgley C, Sparks A, Lane EB and Lane DP. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp Cell Res. 1999; 248(2):457-472.
13. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N and Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303(5659):844-848.
14. Choong ML, Yang H, Lee MA and Lane DP. Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle. 2009; 8(17):2810-2818.
15. Cheok CF, Kua N, Kaldis P and Lane DP. Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death Differ. 2010; 17(9):1486-1500.
16. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA, Jr., Kinzler KW, Vogelstein B and Papadopoulos N. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A. 2009; 106(10):3964-3969.
17. Rao B, van Leeuwen IM, Higgins M, Campbel J, Thompson AM, Lane DP and Lain S. Evaluation of an Actinomycin D/ VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget. 2010; 1(7):639-650.
18. Skribek H, Otvos R, Flaberg E, Nagy N, Markasz L, Eksborg S, Masszi T, Kozma A, Adam E, Miseta A, Klein E and Szekely L. Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin. Exp Hematol. 2010; 38(12):1219-1230.
19. Weinstein JN. Drug discovery: Cell lines battle cancer. Nature. 2012; 483(7391):544-545.
20. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-607.
21. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012; 483(7391):570-575.
22. Mutka SC, Yang WQ, Dong SD, Ward SL, Craig DA, Timmermans PB and Murli S. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res. 2009; 69(2):510-517.
23. Cheok CF, Verma CS, Baselga J and Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol. 2010; 8(1):25-37.
24. Kranz D and Dobbelstein M. A killer promoting survival - p53 as a selective means to avoid side effects of chemotherapy. Cell Cycle. 2012; 11(11):in press.
25. Steelman LS, Martelli AM, Nicoletti F and McCubrey JA. Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity. Oncotarget. 2011; 2(3):109-112.
26. Apontes P, Leontieva OV, Demidenko ZN, Li F and Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget. 2011; 2(3):222-233.
27. van Leeuwen IM and Lain S. Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs. Oncotarget. 2011; 2(4):274-276.
28. Pabla N and Dong Z. Curtailing side effects in chemotherapy: a tale of PKCdelta in cisplatin treatment. Oncotarget. 2012; 3(1):107-111.
29. Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi G and Longo VD. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A. 2008; 105(24):8215-8220.
30. Jiang M, Pabla N, Murphy RF, Yang T, Yin XM, Degenhardt K, White E and Dong Z. Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/ Bak activation. J Biol Chem. 2007; 282(4):2636-2645.
31. Cheok CF. Protecting normal cells from the cytotoxicity of chemotherapy. Cell Cycle. 2012; in press.
32. Raffaghello L, Safdie F, Bianchi G, Dorff T, Fontana L and Longo VD. Fasting and differential chemotherapy protection in patients. Cell Cycle. 2010; 9(22):4474-4476.
33. Lee C, Safdie FM, Raffaghello L, Wei M, Madia F, Parrella E, Hwang D, Cohen P, Bianchi G and Longo VD. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res. 2010; 70(4):1564-1572.
34. Pabla N, Dong G, Jiang M, Huang S, Kumar MV, Messing RO and Dong Z. Inhibition of PKCdelta reduces cisplatininduced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. J Clin Invest. 2011; 121(7):2709-2722.